Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: A pilot kinematic study

European Journal of Neurology

Volumn 15, Issue 6, 2008, Pages 619-626

  Solaro, C ^a,b,d   Brichetto, G ^c   Capello, E ^c   Abuarqub, S ^c   Sanguineti, V ^a,c  

^a Ospedale La Colletta   (Italy)

^b ASL3 Genovese   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NONE   (Italy)

Author keywords

Cerebellar symptoms; Levetiracetam; Movement indicators; Multiple sclerosis

Indexed keywords

ETIRACETAM; PLACEBO;

ADULT; ARTICLE; ATAXIA; CEREBELLUM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; KINEMATICS; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; TREMOR; VISUAL ANALOG SCALE;

BIOMECHANICS; CEREBELLUM; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; NOOTROPIC AGENTS; PILOT PROJECTS; PIRACETAM; TREMOR;

EID: 43549098051     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02129.x     Document Type: Article

References (38)

1. Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. Archives of Neurology 1996 53 : 353 358.
2. Pittock SJ, McClelland RL, Mayr WT, Rodriguez M, Matsumoto JY. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Movement Disorders 2004 19 : 1482 1485.
3. Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in multiple sclerosis. Brain 2001 124 : 720 730.
4. Watts RL, Koller WC. Movement Disorders: Neurologic Principles and Practice. New York : McGrawHill, Health Professions Division, 1997.
5. Sabra AF, Hallett M, Sudarsky L, Mullally W. Treatment of action tremor in multiple sclerosis with isoniazid. Neurology 1982 32 : 912 913.
6. Sechi G, Agnetti V, Sulas FM, et al. Effects of topiramate in patients with cerebellar tremor. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003 27 : 1023 1027.
7. Aisen ML, Holzer M, Rosen M, Dietz M, McDowell F. Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury. Archives of Neurology 1991 48 : 513 515.
8. Henkin Y, Herishanu YO. Primidone as a treatment for cerebellar tremor in multiple sclerosis - two case reports. Israel Journal of Medical Sciences 1989 25 : 720 721.
9. Gbadamosi J, Buhmann C, Moench A, Heesen C. Failure of ondansetron in treating cerebellar tremor in MS patients - an open-label pilot study. Acta Neurologica Scandinavica 2001 104 : 308 311.
10. Monaca-Charley C, Stojkovic T, Duhamel A, De Seze J, Ferriby D, Vermersch P. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. Journal of Neurology 2003 250 : 1190 1194.
11. Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. Journal of Neurology, Neurosurgery and Psychiatry 1997 62 : 282 284.
12. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004 62 : 1105 1109.
13. Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. Journal of Neurology 2006 253 : 762 766.
14. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006 66 : 1654 1660.
15. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000 55 : 236 242.
16. Alsaadi TM, Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure 2003 12 : 154 156.
17. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007 69 : 1751 1760.
18. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001 57 : 1112 1114.
19. Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Movement Disorders 2005 20 : 1610 1614.
20. Krauss GL, Betts T, Abou-Khalil B, Gergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003 12 : 617 620.
21. Schauer R, Singer M, Saltuari L, Kofler M. Suppression of cortical myoclonus by levetiracetam. Movement Disorders 2002 17 : 411 415.
22. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the USA 2004 101 : 9861 9866.
23. Cramer JA, Leppik IE, Rue KD, Edrich P, Kramer G. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Research 2003 56 : 135 145.
24. Alusi SH, Worthington J, Glickman S, Findley LJ, Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2000 68 : 756 760.
25. Sanguineti V, Morasso PG, Baratto L, Brichetto G, Luigi Mancardi G, Solaro C. Cerebellar ataxia: quantitative assessment and cybernetic interpretation. Human Movement Science 2003 22 : 189 205.
26. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983 13 : 227 231.
27. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994 344 : 9 13.
28. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964 192 : 540 542.
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 : 1444 1452.
30. Zigmond AS, Sims AC. The effect of the use of the International Classification of Diseases 9th revision: upon hospital in-patient diagnoses. British Journal of Psychiatry 1983 142 : 409 413.
31. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. Journal of Consulting and Clinical Psychology 1974 42 : 861 865.
32. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. Journal of Neurology, Neurosurgery and Psychiatry 1993 56 : 868 873.
33. Flash T, Hogan N. The coordination of arm movements: an experimentally confirmed mathematical model. Journal of Neuroscience 1985 5 : 1688 1703.
34. Abuarqub S BG, Solaro C, Sanguineti V. Kinetic tremor and visuomotor control in patients with multiple sclerosis. In : Gantchev N, ed. From Basic Motor Control to Functional Recovery - Motor Control Conference. Sofia, Bulgaria : Academic Publishing House 'Prof. M. Drinov', September 2005 : 207 212.
35. Solaro C, Brichetto G, Casadio M, et al. Subtle upper limb impairment in asymptomatic multiple sclerosis subjects. Multiple Sclerosis 2007 13 : 428 432.
36. Solaro C, Brichetto G, Battaglia MA, Messmer Uccelli M, Mancardi GL. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurological Sciences 2005 25 : 307 310.
37. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neuroscience Letters 2001 306 : 5 8.
38. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacological Research 2000 42 : 281 285.